Online citations, reference lists, and bibliographies.

Efficacy And Safety Of Osteoporosis Medications In A Rat Model Of Late-stage Chronic Kidney Disease Accompanied By Secondary Hyperparathyroidism And Hyperphosphatemia

M. Ota, M. Takahata, T. Shimizu, Y. Kanehira, H. Kimura-Suda, Y. Kameda, H. Hamano, S. Hiratsuka, D. Sato, N. Iwasaki
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
SummaryThis study showed that bisphosphonate was safe and effective for the treatment of bone disorders in stage 4 chronic kidney disease (CKD) rats. Intermittent teriparatide therapy showed an anabolic action on bone even under secondary hyperparathyroidism conditions without having an adverse effect on mineral metabolism in late-stage CKD.IntroductionPatients with late-stage CKD are at high risk for fragility fractures. However, there are no consensus on the efficacy and safety of osteoporosis medications for patients with late-stage CKD. In the present study, we aimed to examine the efficacy and safety of alendronate (ALN) and teriparatide (TPD) for treating bone disorder in late-stage CKD with pre-existing secondary hyperparathyroidism using a rat model of CKD.MethodsMale 10-week-old Sprague-Dawley rats were subjected to a 5/6 nephrectomy or sham surgery and randomized into the following four groups: sham, vehicle (saline subcutaneous (sc) daily), ALN (50 μg/kg sc daily), and TPD (40 μg/kg sc daily). Medications commenced at 24 weeks of age and continued for 4 weeks. Micro-computed tomography, histological analysis, infrared spectroscopic imaging, and serum assays were performed.ResultsNephrectomized rats developed hyperphosphatemia, secondary hyperparathyroidism (SHPT), and high creatinine, equivalent to CKD stage 4 in humans. ALN suppressed the bone turnover and increased the degree of mineralization in cortical bone, resulting in an improvement in the mechanical properties. TPD further increased the bone turnover and significantly increased the degree of mineralization, micro-geometry, and bone volume, resulting in a significant improvement in the mechanical properties. Both ALN and TPD had no adverse effect on renal function and mineral metabolism.ConclusionsBP is safe and effective for the treatment of bone disorders in stage 4 CKD rats. Intermittent TPD therapy showed an anabolic action on bone even under SHPT conditions without having an adverse effect on mineral metabolism in late-stage CKD.
This paper references
10.1001/ARCHINTE.167.2.133
Renal function and risk of hip and vertebral fractures in older women.
K. Ensrud (2007)
10.1016/J.BONE.2005.02.002
Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora.
S. Komatsubara (2005)
10.1152/ajprenal.1994.266.5.F706
Impaired homologous upregulation of vitamin D receptor in rats with chronic renal failure.
H. Koyama (1994)
10.1038/boneres.2014.44
Chronic kidney disease and the skeleton
P. Miller (2014)
Studies of the DMP 1 57kDa functional domain both in vivo and in vitro
Y Lu (2009)
10.1359/jbmr.2003.18.11.1932
Recombinant Human Parathyroid Hormone (1–34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure
Y. Jiang (2003)
10.1007/s00198-006-0189-8
Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment
P. Miller (2006)
10.1016/j.bone.2014.04.005
Vitamin K-dependent carboxylation of osteocalcin affects the efficacy of teriparatide (PTH(1-34)) for skeletal repair.
T. Shimizu (2014)
10.1002/jbmr.141
Guidelines for assessment of bone microstructure in rodents using micro–computed tomography
M. Bouxsein (2010)
10.1046/J.1523-1755.2000.00178.X
Increased risk of hip fracture among patients with end-stage renal disease.
A. Alem (2000)
10.1002/jbmr.1805
Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee
D. Dempster (2013)
10.4061/2011/970245
Phosphate Metabolism in CKD Stages 3–5: Dietary and Pharmacological Control
Markus Ketteler (2011)
10.2215/CJN.04040411
Vitamin D therapy in chronic kidney disease and end stage renal disease.
M. Melamed (2012)
10.1210/en.2009-0472
Bone formation regulates circulating concentrations of fibroblast growth factor 23.
R. Samadfam (2009)
10.1016/J.BONE.2006.06.002
The compositional and physicochemical homogeneity of male femoral cortex increases after the sixth decade.
J. Yerramshetty (2006)
10.1016/J.BIOMATERIALS.2006.11.043
FT-IR imaging of native and tissue-engineered bone and cartilage.
A. Boskey (2007)
10.1007/s00223-013-9755-1
Effects of Different Dosages of Parathyroid Hormone-Related Protein 1–34 on the Bone Metabolism of the Ovariectomized Rat Model of Osteoporosis
J. Xu (2013)
10.1359/jbmr.070112
Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial
S. Jamal (2007)
10.1038/ki.2008.264
Chronic kidney disease and bone fracture: a growing concern.
T. Nickolas (2008)
10.1002/JBMR.5650060405
The bisphosphonate alendronate (MK‐217) inhibits bone loss due to ovariectomy in rats
J. Seedor (1991)
Renal function and risk of hip and vertebral fractures in older wom
KE Ensrud (2007)
10.1093/NDT/GFH876
Downregulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone.
Yoshiko Iwasaki-Ishizuka (2005)
10.1111/j.1755-6686.2009.00067.x
Chronic kidney disease-mineral and bone disorder (CKD-MBD): a new term for a complex approach.
F. Švára (2009)
10.1038/ki.2009.188
KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
Supplemental Tables (2009)
10.1038/SJ.KI.5000414
Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
S. Moe (2006)
10.1056/NEJMct1004903
Bisphosphonates for osteoporosis.
M. Favus (2010)
Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review.
P. Bolasco (2009)
(Recombinant Human Parathyroid Hormone or rhPTH) BONMAX
(2013)
10.1053/j.ajkd.2010.02.338
Management of osteoporosis in CKD Stages 3 to 5.
P. Gordon (2010)
10.1359/jbmr.060105
Cortical PQCT Measures Are Associated With Fractures in Dialysis Patients
S. Jamal (2006)
10.1359/JBMR.050817
Safety and Efficacy of Risedronate in Patients With Age‐Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials
P. Miller (2005)
10.1038/ki.1991.2
Role of bone in regulation of systemic acid-base balance.
J. Green (1991)
10.1159/000151727
Studies of the DMP1 57-kDa Functional Domain both in vivo and in vitro
Y. Lu (2008)
10.1016/0140-6736(93)92555-8
Bone density at various sites for prediction of hip fractures
S. Cummings (1993)
10.1038/ki.2013.547
The three-year incidence of fracture in chronic kidney disease.
K. Naylor (2014)
10.1016/j.semnephrol.2009.01.007
Diagnosis and treatment of osteoporosis in chronic renal disease.
P. Miller (2009)
10.1681/ASN.2005111194
Relationship between moderate to severe kidney disease and hip fracture in the United States.
T. Nickolas (2006)
10.1007/s00223-011-9479-z
Circulating Fibroblast Growth Factor-23 Increases Following Intermittent Parathyroid Hormone (1–34) in Postmenopausal Osteoporosis: Association with Biomarker of Bone Formation
G. Hampson (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar